UNSPSC 51373006: Pentazocine hydrochloride

This classification denotes an opioid receptor agonist with the molecular formula C19H27NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A36BXO4PPX, chemically known as 2,6-methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, hydrochloride, (2r,6r,11r)-rel- but more generally known as pentazocine hydrochloride, which bears US NIH Compound Identifier 107799.

UNSPSC 51373006 Pentazocine hydrochloride is a Commodity code that in practice sees minimal state and local procurement activity aligned with its pharmaceutical scope. The single recent opportunity posted under this code—Seminole County, Florida's IFB 60459723LAS—solicits naloxone and drug deactivation systems rather than pentazocine hydrochloride, indicating a mismatch between the code assignment and the work actually being bought. State and local health departments and county public health agencies that do procure controlled pharmaceuticals and opioid antagonists typically source through established pharmaceutical supply chains, cooperative purchasing agreements, or state drug formularies rather than open competitive solicitations.

Seminole County's June 2026 posting sought 1,900 units of naloxone and 800 safe drug deactivation systems annually on an IFB basis, with a response deadline of July 26, 2023 (note the date inconsistency in the source record), and quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The procurement required E-Verify compliance, drug-free workplace certification, and compliance with federal regulations including the Clean Air Act and Federal Water Pollution Control Act, with FEMA funding cited as a potential source. The contract offered an initial two-year term with one-year renewal option. Beyond this single record, the code shows no recent state and local activity; pursue only if your firm maintains direct relationships with county health procurement offices or state pharmacy benefit managers actively seeking branded pharmaceutical sourcing outside standard group purchasing channels.